217 related articles for article (PubMed ID: 32632513)
1. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Borrie AE; Rose FA; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Teft WA; Kim RB
Breast Cancer Res Treat; 2020 Sep; 183(2):365-372. PubMed ID: 32632513
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Gervasini G; Jara C; Olier C; Romero N; Martínez R; Carrillo JA
Br J Clin Pharmacol; 2017 Mar; 83(3):562-571. PubMed ID: 27747906
[TBL] [Abstract][Full Text] [Related]
3. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Henry NL; Skaar TC; Dantzer J; Li L; Kidwell K; Gersch C; Nguyen AT; Rae JM; Desta Z; Oesterreich S; Philips S; Carpenter JS; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2013 Apr; 138(3):807-16. PubMed ID: 23546553
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
[TBL] [Abstract][Full Text] [Related]
5. Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
Borrie AE; Rose RV; Choi YH; Perera FE; Read N; Sexton T; Lock M; Vandenberg TA; Hahn K; Dinniwell R; Younus J; Logan D; Potvin K; Yaremko B; Yu E; Lenehan J; Welch S; Tyndale RF; Teft WA; Kim RB
Breast Cancer Res Treat; 2018 Nov; 172(2):371-379. PubMed ID: 30094551
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
Niravath P; Chen B; Chapman JW; Agarwal SK; Welschhans RL; Bongartz T; Kalari KR; Shepherd LE; Bartlett J; Pritchard K; Gelmon K; Hilsenbeck SG; Rimawi MF; Osborne CK; Goss PE; Ingle JN
Clin Breast Cancer; 2018 Feb; 18(1):78-87. PubMed ID: 29128193
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Cairns J; Ingle JN; Dudenkov TM; Kalari KR; Carlson EE; Na J; Buzdar AU; Robson ME; Ellis MJ; Goss PE; Shepherd LE; Goodnature B; Goetz MP; Weinshilboum RM; Li H; Bari MG; Wang L
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32701512
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
Romero SAD; Su HI; Satagopan J; Li QS; Seluzicki CM; Dries A; DeMichele AM; Mao JJ
Breast; 2020 Feb; 49():48-54. PubMed ID: 31678641
[TBL] [Abstract][Full Text] [Related]
9. Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.
Reinbolt RE; Sonis S; Timmers CD; Fernández-Martínez JL; Cernea A; de Andrés-Galiana EJ; Hashemi S; Miller K; Pilarski R; Lustberg MB
Cancer Med; 2018 Jan; 7(1):240-253. PubMed ID: 29168353
[TBL] [Abstract][Full Text] [Related]
10. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.
Mao JJ; Su HI; Feng R; Donelson ML; Aplenc R; Rebbeck TR; Stanczyk F; DeMichele A
Breast Cancer Res; 2011 Jan; 13(1):R8. PubMed ID: 21251330
[TBL] [Abstract][Full Text] [Related]
11. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
12. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Hack CC; Häberle L; Brucker SY; Janni W; Volz B; Loehberg CR; Hartkopf AD; Walter CB; Baake G; Fridman A; Malter W; Wuerstlein R; Harbeck N; Hoffmann O; Kuemmel S; Martin B; Thomssen C; Graf H; Wolf C; Lux MP; Bayer CM; Rauh C; Almstedt K; Gass P; Heindl F; Brodkorb T; Willer L; Lindner C; Kolberg HC; Krabisch P; Weigel M; Steinfeld-Birg D; Kohls A; Brucker C; Schulz V; Fischer G; Pelzer V; Rack B; Beckmann MW; Fehm T; Rody A; Maass N; Hein A; Fasching PA; Nabieva N
Breast; 2020 Apr; 50():11-18. PubMed ID: 31958661
[TBL] [Abstract][Full Text] [Related]
13. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
14. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Ferraldeschi R; Arnedos M; Hadfield KD; A'Hern R; Drury S; Wardley A; Howell A; Evans DG; Roberts SA; Smith I; Newman WG; Dowsett M
Breast Cancer Res Treat; 2012 Jun; 133(3):1191-8. PubMed ID: 22418701
[TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
Garcia-Giralt N; Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Torres-Del Pliego E; Balcells S; Albanell J; Grinberg D; Diez-Perez A; Tusquets I; Nogués X
Breast Cancer Res Treat; 2013 Jul; 140(2):385-95. PubMed ID: 23868189
[TBL] [Abstract][Full Text] [Related]
17. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
[TBL] [Abstract][Full Text] [Related]
18. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Henry NL; Azzouz F; Desta Z; Li L; Nguyen AT; Lemler S; Hayden J; Tarpinian K; Yakim E; Flockhart DA; Stearns V; Hayes DF; Storniolo AM
J Clin Oncol; 2012 Mar; 30(9):936-42. PubMed ID: 22331951
[TBL] [Abstract][Full Text] [Related]
19. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
[TBL] [Abstract][Full Text] [Related]
20. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Park IH; Lee YS; Lee KS; Kim SY; Hong SH; Jeong J; Lee H; Ro J; Nam BH
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1263-71. PubMed ID: 21442439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]